Figure S2 from Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Year: 2024
Type: other
Abstract: Figure S2: A, MALDI-TOF Mass spectroscopy results show 8.7 equivalents of DOTA molecules on the YS5 antibody. The number of DOTA were calculated by dividing the difference of m/z between YS5 and DOTA-YS5 by the molecular weight of DOTA. B, Size-exclusion chromatogram shows no aggregation of the [225Ac]DOTA-YS5 after the radiolabeling steps. C, Stability of the [225Ac]DOTA-YS5 tested in saline and human serum for 14 days. D, Comparison of the binding assay results after attaining secular equilibrium vs without secular equilibrium. No significant difference was observed for these two assays (n=4). (Data represented as Mean ± SD).
Authors: Anil P. Bidkar, Sinan Wang, Kondapa Naidu. Bobba, Emily Chan, Scott Bidlingmaier, Emily A. Egusa, Robin Peter, Umama Ali, Niranjan Meher, Anju Wadhwa, Suchi Dhrona, Chandrashekhar Dasari, Denis Beckford-Vera, Yang Su, Ryan Tang, Li Zhang, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Jonathan Chou, Bin Liu, Robert R. Flavell
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402818997